Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard Sells 2,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CEO Thomas Sandgaard sold 2,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $8.63, for a total transaction of $17,260.00. Following the sale, the chief executive officer now owns 14,621,350 shares of the company’s stock, valued at $126,182,250.50. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Thomas Sandgaard also recently made the following trade(s):

• On Wednesday, October 30th, Thomas Sandgaard sold 2,000 shares of Zynex stock. The stock was sold at an average price of $8.92, for a total transaction of $17,840.00.

Zynex Price Performance

ZYXI opened at $8.76 on Friday. The company has a market capitalization of $279.01 million, a price-to-earnings ratio of 58.40 and a beta of 0.53. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66. The firm has a 50-day moving average price of $8.11 and a 200-day moving average price of $9.09. Zynex, Inc. has a twelve month low of $7.15 and a twelve month high of $13.77.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings data on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The company had revenue of $49.97 million during the quarter, compared to analyst estimates of $50.83 million. During the same period last year, the business earned $0.10 earnings per share. Zynex’s revenue was up .1% compared to the same quarter last year. Equities analysts expect that Zynex, Inc. will post 0.2 EPS for the current year.

Hedge Funds Weigh In On Zynex

A number of large investors have recently modified their holdings of ZYXI. Millennium Management LLC boosted its position in shares of Zynex by 66.5% in the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after acquiring an additional 118,615 shares during the period. Renaissance Technologies LLC boosted its position in shares of Zynex by 68.7% in the second quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock valued at $1,769,000 after acquiring an additional 77,300 shares during the period. LSV Asset Management boosted its position in shares of Zynex by 45.1% in the first quarter. LSV Asset Management now owns 108,935 shares of the company’s stock valued at $1,348,000 after acquiring an additional 33,840 shares during the period. Janney Montgomery Scott LLC boosted its position in shares of Zynex by 22.3% in the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock valued at $1,179,000 after acquiring an additional 26,368 shares during the period. Finally, WINTON GROUP Ltd lifted its position in Zynex by 147.6% during the second quarter. WINTON GROUP Ltd now owns 36,841 shares of the company’s stock valued at $343,000 after purchasing an additional 21,960 shares during the last quarter. 29.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZYXI. Royal Bank of Canada reduced their target price on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. HC Wainwright lifted their target price on shares of Zynex from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, October 25th.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.